NPX372, a B7-H7:CD3 Bispecific Antibody, in Selected Solid Tumor Malignancies

Summary

NPX372 is an antibody drug (protein drug) that blocks a specific protein which is found to be increased on the surface of cancer cells called B7-H7 and, at the same time, binds to immune cells (T cells) through a receptor called CD3. The effect of this binding is to activate T cells to kill cancer cells with B7-H7. In this research study we are: * Evaluating the safety and possible effectiveness of NPX372. * Identifying a safe and tolerable dose or doses for further study. Participants who are treated will receive an intravenous (IV) infusion of NPX372 if their disease has not progressed, and be closely monitored by the treating physicians.

Timeline

Start

2026-04-01

Primary completion

2027-04-01

Completion

2027-07-01

Drugs

Indications